Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Danaher Corporation (DHR)

NYQ · Diagnostics & Research

$199.05+2.55 (+1.30%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$139.93B
P/E (TTM)
35.11
EPS
$5.67
Div Yield
0.81%
52W Range
$160.93–$242.80
Beta
0.82

Company overview

Next earnings: 2026-10-20(84d)

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Peers in Diagnostics & Research

All in industry →

Recent press releases

April 2026

3 months ago424B5Healthcare

Danaher Raises €3 Billion in Bonds to Fund Masimo Acquisition

DHRDANAHER CORP /DE/

# 🧾 What This Document Is This is a **prospectus supplement** filed with the SEC. It’s a legal document that provides the specific details for a new bond offering by Danaher Corporation. Think of it as the detailed menu and terms for a big loan the company is taking out. It updates a broader pros

Read summaryView on SEC EDGAR
3 months ago424B5Healthcare

Danaher (DHR) issues debt for proposed Masimo acquisition funding

DHRDANAHER CORP /DE/

# 📄 What This Document Is 📝 This document is a preliminary prospectus supplement filed by Danaher Corporation (DHR). Think of it as a detailed pre-sale guidebook for a massive debt offering. Since this is a "supplement," it adds specific information about the new bonds (notes) being sold to a muc

Read summaryView on SEC EDGAR
3 months ago8-KHealthcare

DHR announces Masimo acquisition and raises full-year guidance for 2026

DHRDANAHER CORP /DE/

# 📜 What This Document Is 🗓️ This report summarizes Danaher Corporation's (DHR) results for the first quarter of 2026, filed as an 8-K with the SEC. This type of filing is used to announce major corporate events or periodic results to the public immediately. The filing contains the company's fina

Read summaryView on SEC EDGAR

SEC filings

All filings →
3 recent filings shown in the timeline above. View all SEC filings →

Danaher Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →

No 13F holdings have been reported for Danaher Corporation in this window.

People at Danaher Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$439.0M
NI $954.0M
06/25
$294.0M
NI $555.0M
09/25
$6.05B
NI $908.0M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $1.27
Prior: $0.77
Revenue sparkline